Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Acquires $100,500.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith acquired 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was acquired at an average price of $1.34 per share, for a total transaction of $100,500.00. Following the completion of the transaction, the director directly owned 1,519,178 shares in the company, valued at approximately $2,035,698.52. This represents a 5.19% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

MAIA Biotechnology Stock Up 4.9%

MAIA Biotechnology stock opened at $1.50 on Friday. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $3.19. The firm’s 50-day simple moving average is $1.32 and its 200 day simple moving average is $1.53. The firm has a market capitalization of $91.20 million, a PE ratio of -2.24 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. On average, research analysts expect that MAIA Biotechnology, Inc. will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after purchasing an additional 25,684 shares during the last quarter. Jane Street Group LLC acquired a new position in MAIA Biotechnology in the 4th quarter valued at about $120,000. Marshall Wace LLP acquired a new position in MAIA Biotechnology in the 2nd quarter valued at about $29,000. Corsair Capital Management L.P. acquired a new position in MAIA Biotechnology in the 1st quarter valued at about $140,000. Finally, Centric Wealth Management raised its stake in MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after purchasing an additional 11,500 shares during the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.